Cargando…
Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T
BACKGROUND: Cardiac hypertrophy is a major risk factor for morbidity and mortality in a number of cardiovascular diseases. Consequently, the signaling pathways that inhibit cardiac hypertrophy are currently receiving much interest. Among them, nitric oxide (NO), signaling via cGMP and cGMP-dependent...
Autores principales: | Hassan, Madiha AH, Ketat, Amal F |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2005
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1131906/ https://www.ncbi.nlm.nih.gov/pubmed/15813973 http://dx.doi.org/10.1186/1471-2210-5-10 |
Ejemplares similares
-
Role of cGMP and cAMP in the hemodynamic response to intrathecal sildenafil administration
por: Bombarda, Gabriela, et al.
Publicado: (2011) -
Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP efflux
por: Subbotina, Anna, et al.
Publicado: (2017) -
Why sildenafil and sildenafil citrate monohydrate crystals are not stable?
por: Sawatdee, Somchai, et al.
Publicado: (2015) -
NO/cGMP signalling in platelets
por: Schinner, Elisabeth, et al.
Publicado: (2009) -
cGMP and cardiac hypertrophy
por: Perera, Ruwan K, et al.
Publicado: (2015)